

March 12, 2018

Dear Healthcare Provider:

As a valued health care provider, we want to share with you that Orexigen Therapeutics, Inc. has announced the decision to sell all of the assets of the company by the end of June using a structured process through Chapter 11 of the U.S. Bankruptcy Code. In light of this decision, we wanted to take this opportunity to reassure you that we remain as committed as ever to serving you and your patients. This will not affect your ability to prescribe Contrave® (naltrexone HCl and bupropion HCl extended release) or for your patients to start and stay on CONTRAVE. Through this sales process, Orexigen's normal day-to-day operations will continue without interruption.

Orexigen was founded on the premise of helping to improve the health and lives of patients struggling to lose weight, and we remain as committed as ever to that mission. CONTRAVE is the #1 prescribed weight loss brand and almost 800,000 patients have benefitted from CONTRAVE since launch¹. We owe much of that to you and your partnership in the war on obesity, but we also know that many more patients could benefit. Through this near-term sale, along with our continued, active promotion, and support from partners such as yourself, we confidently intend to serve the growing patient demand.

Below are answers to some questions you may have.

1. Will there be any disruption of the availability of CONTRAVE at the pharmacy?
 - a. No, CONTRAVE will continue to be available at the pharmacy. CONTRAVE will also continue to be available via our Free Home Delivery mail order pharmacy partner. If you are interested in giving your patients the convenience of Free Home Delivery please visit: <https://contravehcp.com/savings-support/>
2. Will any other programs or services be disrupted?
 - a. No, all programs and services will continue such as our savings card program, Free Home Delivery (FHD) service; and our Direct Account contracting for practice dispensing program.
3. Will there be any medical education programs during this transition process?
 - a. No, at this time, there are no current plans to conduct medical education programs. We will continue to evaluate efficient alternatives to support education of physicians and patients.
4. Who should I contact if I have any further questions?
 - a. Your primary point of contact will remain your Health Science Associate.

If you have not visited our website recently, we encourage you to do so. There is a tremendous amount of information there, both for providers and for patients. A few examples include information on our savings card, employer insurance coverage and tips on diet and exercise for patients.

Here are links to both of our websites:

www.contrave.com (for patients)

www.contravehcp.com (for providers)

CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m² or greater (obese), or adults with a BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.

One of the ingredients in CONTRAVE, bupropion, may increase the risk of suicidal thinking in children, adolescents, and young adults. CONTRAVE patients should be monitored for suicidal thoughts and behaviors. In patients taking bupropion for smoking cessation, serious neuropsychiatric adverse events have been reported. CONTRAVE is not approved for use in children under the age of 18.

Thank you for all you have done to support us up until now and thank you in advance for your ongoing support as we transition through this process.

Very truly yours,



Michael Narachi
President & Chief Executive Officer